View Item 

Show simple item record

On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII

dc.contributor.authorSørensen, B.en_US
dc.contributor.authorDargaud, Y.en_US
dc.contributor.authorKenet, G.en_US
dc.contributor.authorLusher, Jeanne M.en_US
dc.contributor.authorMumford, A.en_US
dc.contributor.authorPipe, Steven W.en_US
dc.contributor.authorTiede, A.en_US
dc.date.accessioned2012-03-16T15:53:01Z
dc.date.available2013-05-01T17:24:42Zen_US
dc.date.issued2012-03en_US
dc.identifier.citationSørensen, B. ; Dargaud, Y. ; Kenet, G. ; Lusher, J. ; Mumford, A. ; Pipe, S. ; Tiede, A. (2012). "Onâ demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII." Haemophilia 18(2). <http://hdl.handle.net/2027.42/90042>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90042
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherRecombinant Activated Factor VIIen_US
dc.subject.otherHaemophiliaen_US
dc.subject.otherInhibitoren_US
dc.subject.otherTreatment Strategiesen_US
dc.titleOn‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIIen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherHannover Medical School, Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover, Germanyen_US
dc.contributor.affiliationotherHaemostasis Research Unit, Centre for Haemostasis & Thrombosis, Guy’s & St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London, UKen_US
dc.contributor.affiliationotherUnité d’Hémostase Clinique, Hôpital Edouard Herriot, Lyon, Franceen_US
dc.contributor.affiliationotherNational Hemophilia Center, Sheba Medical Center, Tel‐Hashomer, Israelen_US
dc.contributor.affiliationotherDepartment of Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI, USAen_US
dc.contributor.affiliationotherBristol Haemophilia Centre, Bristol Haematology and Oncology Centre, Bristol, UKen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90042/1/j.1365-2516.2011.02612.x.pdf
dc.identifier.doi10.1111/j.1365-2516.2011.02612.xen_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceTengborn L. Fibrinolytic Inhibitors in the Management of Bleeding Disorders. Canada: WFH publications, Treatment of Hemophilia; No. 42 (April 2007 ).en_US
dc.identifier.citedreferenceTeitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high‐titre inhibitors. Haemophilia 2007; 13: 256 – 63.en_US
dc.identifier.citedreferenceKey NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912 – 8.en_US
dc.identifier.citedreferenceKavakli K, Makris M, Zulfikar B et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi‐centre, randomised, double‐blind, cross‐over trial. Thromb Haemost 2006; 95: 600 – 5.en_US
dc.identifier.citedreferenceSantagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367 – 71.en_US
dc.identifier.citedreferenceYoung G, Shafer FE, Rojas P, Seremetis S. Single 270 μg kg −1 ‐dose rFVIIa vs. standard 90 μg kg −1 ‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287 – 94.en_US
dc.identifier.citedreferenceAbshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899 – 909.en_US
dc.identifier.citedreferenceCroom KF, McCormack PL. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs 2008; 22: 121 – 36.en_US
dc.identifier.citedreferenceShapiro A. Inhibitor treatment: state of the art. Dis Mon 2003; 49: 22 – 38.en_US
dc.identifier.citedreferenceAstermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546 – 51.en_US
dc.identifier.citedreferenceLusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7 – 10.en_US
dc.identifier.citedreferenceLusher JM. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment. Blood Coagul Fibrinolysis 1998; 9 ( Suppl. 1 ): S111 – 4.en_US
dc.identifier.citedreferenceLusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11 ( Suppl. 1 ): S45 – 9.en_US
dc.identifier.citedreferenceSalaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752 – 9.en_US
dc.identifier.citedreferenceAbshire TC. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing. Semin Hematol 2004; 41 ( Suppl. 1 ): 3 – 7.en_US
dc.identifier.citedreferenceSantagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22 – 6.en_US
dc.identifier.citedreferenceEscobar MA. Health economics in haemophilia: a review from the clinician’s perspective. Haemophilia 2010; 16 ( Suppl. 3 ): 29 – 34.en_US
dc.identifier.citedreferenceVillar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven ® ) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352 – 9.en_US
dc.identifier.citedreferenceBeyer R, Ingerslev J, Sorensen B. Muscle bleeds in professional athletes – diagnosis, classification, treatment and potential impact in patients with haemophilia. Haemophilia 2010; 16: 858 – 65.en_US
dc.identifier.citedreferenceBeyer R, Ingerslev J, Sorensen B. Current practice in the management of muscle haematomas in patients with severe haemophilia. Haemophilia 2010; 16: 926 – 31.en_US
dc.identifier.citedreferenceYoung G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598 – 604.en_US
dc.identifier.citedreferenceNair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global haemostasis and their applications in bleeding disorders. Haemophilia 2010; 16 ( Suppl. 5 ): 85 – 92.en_US
dc.identifier.citedreferenceLevi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. Int J Hematol 2002; 76 ( Suppl. 2 ): 139 – 44.en_US
dc.identifier.citedreferenceHedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747 – 57.en_US
dc.identifier.citedreferenceAbshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898 – 902.en_US
dc.identifier.citedreferenceLindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638 – 48.en_US
dc.identifier.citedreferenceSoucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96: 437 – 42.en_US
dc.identifier.citedreferenceMonroe DM. Further understanding of recombinant activated factor VII mode of action. Semin Hematol 2008; 45 ( Suppl. 1 ): S7 – 11.en_US
dc.identifier.citedreferenceOvanesov MV, Panteleev MA, Sinauridze EI et al. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. Blood Coagul Fibrinolysis 2008; 19: 743 – 55.en_US
dc.identifier.citedreferencePruthi RK, Schmidt KA, Slaby JA, Rodriguez V. Platelet dysfunction induced by herbal supplements in a patient with mild hemophilia A. J Thromb Haemost 2007; 5: 2556 – 8.en_US
dc.identifier.citedreferenceDiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 ( Suppl. 1 ): 1 – 22.en_US
dc.identifier.citedreferenceValentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134 – 46.en_US
dc.identifier.citedreferenceBerntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12 ( Suppl. 6 ): 1 – 7.en_US
dc.identifier.citedreferenceGringeri A, Mannucci PM, Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611 – 9.en_US
dc.identifier.citedreferenceHay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Br J Haematol 2000; 111: 78 – 90.en_US
dc.identifier.citedreferenceHay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591 – 605.en_US
dc.identifier.citedreferenceMathew P. Current opinion on inhibitor treatment options. Semin Hematol 2006; 43 ( Suppl. 4 ): S8 – 13.en_US
dc.identifier.citedreferencePaisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia 2003; 9: 405 – 17.en_US
dc.identifier.citedreferencePerez Bianco R, Ozelo MC, Villaca PR et al. Diagnosis and treatment of congenital hemophilia with inhibitors a Latin American perspective. Medicina (B Aires) 2008; 68: 227 – 42.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2516.2011.02612.x.pdf
Size:
196.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.